Armando Sardi, MD, FACS (he/him/his)

Medical Director
The Institute for Cancer Care, Mercy Medical Center

Armando Sardi, M.D., currently serves as Medical Director of The Institute for Cancer Care at Mercy in Baltimore, Maryland. He is a respected and internationally renowned surgical oncologist who has been honored by multiple organizations for his ongoing contributions as a surgeon and humanitarian.
He is considered to be among the foremost experts in HIPEC surgery. He has performed over 1,000 HIPEC procedures since 1994 and continues to actively contribute to related surgical advances through mentoring, research, and lectureships.
Dr. Sardi is committed to elevating best-in-practice cancer care treatments through a range of initiatives. He co-Chairs Mercy’s Cancer Committee and has been distinguished in Colombia, as one of the 100 Most Influential Expatriates – an honor received, in part, for the medical care he provides through the non-profit organization, Partners for Cancer Care and Prevention. This organization was the recipient of the Conquer Cancer Foundation's Inaugural International Innovation Grant. Additionally, Dr. Sardi was named to a list of Medical Geniuses that Make Colombia Proud.
He has been widely recognized for his leadership and expertise in the oncology field. Some of his awards include:
• Named by Baltimore magazine a "Top Doctor" in the Surgical Oncology specialty
• Named by Castle Connolly Medical Ltd. as one of "America's Top Doctors" in Surgery
• Named by Castle Connolly Medical Ltd. as one of "America’s Top Doctors for Cancer
• Hispanic Hero Award for Excellence as a Medical/Social Entrepreneur” Presented by USHYEE
• Honored by Fusionarte as one of “100 Colombianos” who represent the talent, creativity and perseverance of Colombia.
• Gold Star Teamwork Award” Presented by The Sisters of Mercy in recognition of Gold Star performance
• Education & Fellowships
• Fellowship – Ohio State University
• Residency – Saint Agnes Hospital, Baltimore, MD
• Medical Degree – Universidad del Valle, Colombia

Poster(s):

• E339: Predicting 90-Day Readmissions Following Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: A Nested Case-Control Study

• E356: Systemic Inflammatory Markers: Predictors for Early Morbidity and Survival in Appendiceal Cancer Patients Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy

• P50: Beyond Standard Measures: A Comprehensive Evaluation of Quality of Life in Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy Survivors